BE566423A - - Google Patents
Info
- Publication number
- BE566423A BE566423A BE566423DA BE566423A BE 566423 A BE566423 A BE 566423A BE 566423D A BE566423D A BE 566423DA BE 566423 A BE566423 A BE 566423A
- Authority
- BE
- Belgium
- Prior art keywords
- acid
- pharmaceutical
- mgr
- diiodo
- hydroxyphenoxy
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- HKJUOMPYMPXLFS-UHFFFAOYSA-N 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzoic acid Chemical compound IC1=CC(C(=O)O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 HKJUOMPYMPXLFS-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002775 capsule Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE566423A true BE566423A (enrdf_load_stackoverflow) |
Family
ID=186560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE566423D BE566423A (enrdf_load_stackoverflow) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE566423A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2433943A1 (fr) * | 1977-06-03 | 1980-03-21 | Berema Sa | Preparations medicamenteuses notamment pour le traitement de l'hypercholesterolemie |
-
0
- BE BE566423D patent/BE566423A/fr unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2433943A1 (fr) * | 1977-06-03 | 1980-03-21 | Berema Sa | Preparations medicamenteuses notamment pour le traitement de l'hypercholesterolemie |
| FR2515961A1 (fr) * | 1977-06-03 | 1983-05-13 | Berema Sa | Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie |
| FR2515962A1 (fr) * | 1977-06-03 | 1983-05-13 | Berema Sa | Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie |
| FR2520230A1 (fr) * | 1977-06-03 | 1983-07-29 | Berema Sa | Preparations medicamenteuses contenant un derive d'acide tetraiodothyro-carboxylique notamment pour le traitement de l'hypercholesterolemie |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0316993B1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| FR2688405A1 (fr) | Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant. | |
| US20240216318A1 (en) | Two-component composition | |
| FR2530468A1 (fr) | Composition analgesique et anti-inflammatoire contenant de l'ibuprofen | |
| AU782564B2 (en) | Treatment of fibromyalgia with Ubiquinone 10 and succinic acid | |
| BE897058A (fr) | Utilisation d'un derive du spiro-succinimide dans le traitement de la demence du type alzheimer | |
| US6441041B1 (en) | (-)-hydroxycitric acid for the prevention of osteoporosis | |
| BE566423A (enrdf_load_stackoverflow) | ||
| JPS63183524A (ja) | 記憶向上におけるα−２Ｉ選択性アドレナリンリセプタ作用物質の使用 | |
| EP1569635B1 (en) | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause | |
| BE1000265A3 (fr) | Nouvelle association medicamenteuse. | |
| AU651824B2 (en) | Pharmaceutical composition | |
| JPH01186883A (ja) | 抗アテローム性動脈硬化症剤としてのｄｌ‐５‐〔（２ベンジル‐３，４‐ジヒドロ‐２Ｈ‐ベンゾピラン‐６‐イル）メチル〕チアゾリジン‐２，４‐ジオン | |
| US4565830A (en) | Method of ameliorating the subjective symptoms and objective signs in congestive heart failure | |
| JP3150642B2 (ja) | 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法 | |
| JPH0354644B2 (enrdf_load_stackoverflow) | ||
| RU2182016C2 (ru) | Спазмолитическая композиция, способ получения спазмолитической композиции | |
| BE1005615A3 (fr) | Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant. | |
| US4895843A (en) | Use of 3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid as a hypouricaemic agent | |
| JP2538422B2 (ja) | ５―フルオロウラシル類により起こる炎症の発生を抑制する非注射剤形態の制癌剤 | |
| FR2691630A1 (fr) | Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1. | |
| FR2566664A1 (fr) | Composition utile au traitement de la diarrhee contenant du dextromethorphan | |
| US20050256088A1 (en) | Pharmaceutical nitrones | |
| JPS59222412A (ja) | 心臓疾患治療薬 | |
| EP0698390A1 (en) | Use of bifemelane for the manufacture of a medicament for the treatment of hyperkinetic disorders |